Mont-Saint-Guibert, Belgium; January 16, 2024, 10:01 p.m. CET – Celyad Oncology (Euronext: CYAD) (the “Company”), today publishes an update of its activities for the fourth fiscal quarter of 2023, as well as its outlook for the year 2024.
Michel Lussier, Acting Chief Executive Officer of Celyad Oncology, commented: “2023 was a very important year for Celyad Oncology, following the changes in 2022. Our research team has made remarkable progress in expanding the range of indications cancers potentially targeted by chimeric antigen receptor T cells (CAR-T) and to better combat the main limitations of current CAR T therapies. We have shared new data at several scientific and commercial conferences throughout the year, and we have also published in high-impact peer-reviewed scientific journals. We look forward to seeing the impact of our efforts to unlock the power of our intellectual property and stay at the forefront of next-generation CAR-T cell development.”